Gabriel Andre Leiva-Torres
Overview
Explore the profile of Gabriel Andre Leiva-Torres including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
90
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Theiler C, Lomas-Francis C, Vege S, Chevrier M, Leiva-Torres G, Keller M, et al.
Immunohematology
. 2024 Dec;
40(4):159-165.
PMID: 39740012
Variant D antigens can cause variable serologic results when typing with Anti-D reagents. There is limited information regarding the ability of Anti-D reagents to differentiate between D variants defined by...
2.
Bienz M, Constanzo-Yanez J, Baillargeon N, Leiva-Torres G, Boileau M, Cloutier M, et al.
Transfusion
. 2024 Dec;
65(1):234-239.
PMID: 39623742
Background: Homozygous inheritance of the R haplotype, characterized by the absence of the high frequency antigen Sec, as well as partial C and e antigens, is rare and is associated...
3.
Robitaille N, Leiva-Torres G
Blood
. 2024 Nov;
144(19):1982-1983.
PMID: 39509124
No abstract available.
4.
Leiva-Torres G, Cigna M, Constanzo-Yanez J, St-Louis M, Perreault J, Lavoie J, et al.
Transfusion
. 2024 Mar;
64(4):716-726.
PMID: 38497419
Background: Red blood cell transfusion is an effective treatment for patients with sickle cell disease (SCD). Alloimmunization can occur after a single transfusion, limiting further usage of blood transfusion. It...
5.
Cigna M, Leiva-Torres G, Baillargeon N, Yanez J, Robitaille N
Transfusion
. 2024 Jan;
64(3):554-559.
PMID: 38205646
Background: Hematopoietic stem cell transplant (HSCT) is currently the only widely available curative option for patients with sickle cell disease (SCD). Alloimmunization in this population is frequent and can complicate...
6.
Latour C, Gaussen A, Beaudoin J, Leiva-Torres G, Rochette S, Robitaille N
Vox Sang
. 2023 Aug;
118(10):854-862.
PMID: 37589206
Background And Objectives: ABO antigens are among the most immunogenic, but the haemolytic risks of ABO incompatibilities involving a donor with a weak ABO phenotype are little documented. Materials And...
7.
Lemieux W, Perreault J, Leiva-Torres G, Baillargeon N, Yanez J, Chevrier M, et al.
Future Virol
. 2023 Feb;
PMID: 36844192
More data is required regarding the association between HLA allele and red blood cell (RBC) antigen expression in regard to SARS-CoV-2 infection and COVID-19 susceptibility. ABO, RhD, 37 other RBC...
8.
Morin P, Perreault J, St-Louis M, Leiva-Torres G, Robitaille N, Trepanier P
Vox Sang
. 2022 Mar;
117(7):943-948.
PMID: 35297064
Background And Objectives: A high proportion of suspected weak D patients referred to Héma-Québec were genotyped as weak D type 42 (368/2105, 17.5%). These patients are currently considered D with...
9.
Leiva-Torres G, Lavoie J, Ethier C, Constanzo-Yanez J, Baillargeon N
Transfusion
. 2021 Jul;
61(9):E65-E66.
PMID: 34310722
No abstract available.
10.
Leiva-Torres G, Chevrier M, Constanzo-Yanez J, Lewin A, Lavoie J, Laganiere J, et al.
Transfusion
. 2021 Jun;
61(9):2727-2735.
PMID: 34121202
Background: The determination of the RhD phenotype is crucial to avoid alloimmunization, especially in childbearing women. Following the 2015 recommendation from the Work Group on RHD Genotyping, a large-scale RHD...